Skip to main content

Table 3 The association between multimorbidity, ploypahrmacy, chronic diseases, and abdominal obesity with number of parity

From: The association of parity number with multimorbidity and polypharmacy among Iranian women in the Azarcohort: a cross-sectional study

 

Number of parity

0

1–2

P

3–4

P

5–6

P

7–8

P

 ≥ 9

P

N(%)

N(%)

 

N(%)

 

N(%)

 

N(%)

 

N(%)

 

Multimorbidity

 Model1

Reference

1.22(1.01–1.46)

0.03

2.21(1.84–2.65)

< 0.001

4.12(3.36–5.04)

< 0.001

5.12(4.04–6.48)

< 0.001

5.87(4.51–7.63)

< 0.001

 Model2

Reference

1.46(1.20–1.78)

0.001

1.90(1.56–2.31)

< 0.001

2.28(1.82–2.85)

< 0.001

2.19(1.68–2.85)

< 0.001

2.18(1.62–2.93)

< 0.001

Poly pharmacy

 Model1

Reference

0.88(0.73–1.06)

0.19

1.21(1.00–1.45)

0.04

2.36(1.92–2.89)

 < 0.001

3.26(2.58–4.11)

< 0.001

3.47(2.70–4.47)

< 0.001

 Model2

Reference

1.07(0.88–1.32)

0.46

1.09(0.89–1.34)

0.35

1.34(1.07–1.68)

0.01

1.38(1.07–1.79)

0.01

1.22(0.91–1.62)

0.17

Hypertension

 Model1

Reference

0.68(0.52–0.89)

0.005

1.44(1.12–1.86)

0.004

3.28(2.51–4.27)

< 0.001

4.82(3.60–6.44)

< 0.001

6.04(4.43–8.23)

< 0.001

 Model2

Reference

1.18(0.88–1.58)

0.26

1.36(1.02–1.80)

0.03

1.37(1.02–1.85)

0.03

1.26(0.90–1.75)

0.16

1.20(0.84–1.72)

0.29

Diabetes

 Model1

Reference

1.12(0.74–1.68)

0.57

1.88(1.27–2.79)

0.002

4.56(3.05–6.80)

< 0.001

5.69(3.74–8.66)

< 0.001

6.73(4.37–10.38)

< 0.001

 Model2

Reference

1.56(1.02–2.37)

0.03

1.74(1.15–2.61)

0.008

2.65(1.74–4.04)

< 0.001

2.54(1.62–3.99)

< 0.001

2.65(1.65–4.24)

< 0.001

Stroke

 Model1

Reference

1.43(0.17–11.51)

0.73

2.61(0.34–19.75)

0.35

7.65(1.01–57.52)

0.05

8.0(1.01–63.44)

0.04

15.23(1.97–117.68)

0.009

 Model2

Reference

2.06(0.24–17.16)

0.50

2.11(0.27–16.29)

0.47

3.05(0.39–23.72)

0.28

2.09(0.24–17.57)

0.49

3.26(0.39–27.15)

0.27

CVD

 Model1

Reference

0.44(0.23–0.85)

0.01

1.31(0.73–2.35)

0.36

2.80(1.55–5.09)

0.001

4.41(2.39–8.15)

< 0.001

5.28(2.82–9.88)

< 0.001

 Model2

Reference

0.78(0.39–1.53)

0.47

1.38(0.75–2.54)

0.29

1.49(0.79–2.81)

0.20

1.63(0.84–3.18)

0.14

1.62(0.81–3.22)

0.16

Fatty liver

 Model1

Reference

1.30(0.76–2.21)

0.33

1.81(1.08–3.06)

0.02

2.47(1.43–4.25)

0.001

2.10(1.15–3.82)

0.01

2.86(1.56–5.25)

0.001

 Model2

Reference

1.45(0.83–2.52)

0.18

1.67(0.97–2.88)

0.06

1.88(1.05–3.34)

0.03

1.43(0.75–2.75)

0.27

1.84(0.94–3.60)

0.07

Cancers

 Model1

Reference

0.77(0.22–2.73)

0.69

0.92(0.26–3.15)

0.89

1.54(0.42–5.55)

0.50

2.65(0.71–9.87)

0.14

2.91(0.74–11.33)

0.12

 Model2

Reference

0.93(0.25–3.48)

0.92

0.92(0.25–3.34)

0.90

1.01(0.25–4.02)

0.98

1.33(0.31–5.75)

0.69

1.24(0.27–5.73)

0.77

Depression

 Model1

Reference

1.19(0.93–1.52)

0.15

1.44(1.13–1.84)

0.003

1.58(1.22–2.05)

0.001

1.71(1.28–2.29)

 < 0.001

1.36(0.98–1.8)

0.06

 Model2

Reference

1.28(0.99–1.66)

0.05

1.47(1.14–1.91)

0.003

1.58(1.19–2.11)

0.002

1.67(1.20–2.32)

0.001

1.29(0.90–1.86)

0.16

Rheumatoid Disease

 Model1

Reference

1.34(0.77–2.32)

0.29

1.48(0.86–2.55)

0.15

2.23(1.27–3.93)

0.005

1.67(0.88–3.16)

0.11

1.94(1.00–3.78)

0.04

 Model2

Reference

1.24(0.70–2.20)

0.44

1.22(0.69–2.14)

0.48

1.53(0.84–2.79)

0.16

1.05(0.53–2.11)

0.87

1.17(0.56–2.43)

0.66

COPD

 Model1

Reference

0.65(0.39–1.08)

0.09

0.91(0.56–1.49)

0.72

1.43(0.85–2.38)

0.16

1.52(0.86–2.68)

0.14

2.56(1.46–4.46)

0.001

 Model2

Reference

0.64(0.37–1.09)

0.10

0.89(0.53–1.49)

0.66

1.24(0.71–2.18)

0.44

1.19(0.63–2.26)

0.58

1.93(1.01–3.68)

0.04

Obesity

 Model1

Reference

1.40(1.14–1.72)

0.001

2.32(1.89–2.84)

< 0.001

2.60(2.08–3.25)

 < 0.001

2.35(1.82–3.03)

 < 0.001

2.22(1.68–2.92)

< 0.001

 Model2

Reference

1.35(1.08–1.68)

0.007

1.98(1.59–2.46)

< 0.001

2.15(1.69–2.75)

 < 0.001

1.91(1.44–2.54)

 < 0.001

1.82(1.33–2.48)

< 0.001

Abdominal obesity (WC ≥ 88 cm)

 Model1

Reference

1.61(1.32–1.95)

< 0.001

3.10(2.54–3.77)

< 0.001

4.54(3.61–5.72)

< 0.001

5.08(3.83–6.73)

< 0.001

4.35(3.21–5.89)

< 0.001

 Model2

Reference

1.70(1.37–2.10)

 < 0.001

2.52(2.03–3.13)

< 0.001

2.78(2.15–3.59)

< 0.001

2.67(1.94–3.66)

< 0.001

2.09(1.48–2.96)

< 0.001

WHR ≥ 0.85

 Model1

Reference

1.22(1.01–1.49)

0.03

2.16(1.78–2.62)

< 0.001

4.70(3.73–5.91)

< 0.001

7.18(5.31–9.71)

< 0.001

8.96(6.25–12.86)

< 0.001

 Model2

Reference

1.56(1.26–1.95)

< 0.001

1.86(1.49–2.32)

< 0.001

2.20(1.69–2.85)

< 0.001

2.34(1.67–3.28)

< 0.001

2.40(1.61–3.58)

< 0.001

WHtR ≥ 0.5

 Model1

Reference

2.10(1.65–2.68)

< 0.001

4.92(3.77–6.42)

< 0.001

8.44(5.73–12.44)

 < 0.001

12.91(7.01–23.78)

< 0.001

9.97(5.27–18.84)

< 0.001

 Model2

Reference

1.97(1.47–2.65)

< 0.001

3.22(2.35–4.41)

< 0.001

3.76(2.40–5.86)

 < 0.001

4.79(2.44–9.39)

< 0.001

3.25(1.60–6.64)

< 0.001

  1. Model1 was unadjusted
  2. Model2 was adjusted for age, education level, WSI (wealth score index), Residential regions, marital status,metabolic equivalents task (METs)